VTGN News
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million.
Vistagen Therapeutics (NASDAQ:VTGN) sharesread more...
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers
Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million.
Vistagen Therapeutics (NASDAQ:VTGN) sharesread more...
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers
IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million.
Vistagen Therapeutics (NASDAQ:VTGN) shares increased byread more...
Benzinga
After a Phase 3 Miss, Vistagen Drops New Data Bomb on Fasedienol
Vistagen (NASDAQ:VTGN) has given investors a potentially important new piece of the fasedienol puzzle, but one that needs to be viewed alongside a major setback earlier this year.
24-7 Market News
SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics
SRX Global (NYSE American: SRXH) announced that it has acquired a stake in Vistagen Therapeutics (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal neuroscience therapies based on its proprietary pherine platform. SRX said the investment aligns with its strategy of creating long-term shareholder value through investments in high-conviction operating companies and strategic assets. SRX said it […]
Investor Brand Network
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the topline results of the PALISADE-4 Phase 3 trial of...
Business Wire
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year ended March 31, 2026...
Business Wire
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Companys clinical program for fasedienol nasal spray...
Business Wire
Veeva Systems (VEEV) Q1 Earnings and Revenues Surpass Estimates
Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm PR Newswire NEW YORK, June 1, 2026 NEW YORK, June 1, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire